Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α2- versus α1-GABAa-receptor complexes

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Jensen, Henrik Sindal ^a   Nichol, Kathryn ^b   Lee, Deborah ^b   Ebert, Bjarke ^a  

^a H LUNDBECK A S   (Denmark)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; CLOBAZAM; CLONAZEPAM; NORCLOBAZAM; ZOLPIDEM; 4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; N-DESMETHYLCLOBAZAM; PROTEIN BINDING; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BRAIN HOMOGENATE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; ANIMAL; BINDING SITE; BRAIN; CHEMISTRY; HEK293 CELL LINE; KINETICS; METABOLISM; MOUSE; MUTATION; SEIZURES;

ALLOSTERIC SITE; ANIMALS; ANTICONVULSANTS; BENZODIAZEPINES; BINDING SITES; BRAIN; CLONAZEPAM; HEK293 CELLS; HUMANS; KINETICS; MALE; MICE; MUTATION; PROTEIN BINDING; PYRIDINES; RATS; RECEPTORS, GABA-A; SEIZURES;

EID: 84895756650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088456     Document Type: Article

References (33)

1. A Receptor, in Handbook of Contemporary Neuropharmacology, John Wiley & Sons, Inc.
2. A receptor subtypes. Nature 401: 796-800.
3. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor alpha1 subtype. Nat Neurosci 3: 587-592. (Pubitemid 30332078)
4. A receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. J Psychopharmacol 21: 384-391.
5. A receptor subtypes. Nat Rev Drug Discov 10: 685-697.
6. A receptor modulators as hypnotics. Psychopharmacol 11: 1601-1612.
7. Möhler H, Fritschy JM, Crestani F, Hensch T, Rudolph U (2004) Specific GABA(A) circuits in brain development and therapy. Biochem Pharmacol 68: 1685-1690. (Pubitemid 39286473)
8. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, et al. (1994) Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 18: 355-372. (Pubitemid 24258708)
9. A receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci U S A 102: 915-920.
10. Löw K, Crestani F, Keist R, Benke D, Brünig I, et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 6: 131-134.
11. A receptor subtypes. Nature 451: 330-334.
12. A receptors for the development of tolerance to the sedative action of diazepam in mice. J Neurosci 24: 6785-6790.
13. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg M, on behalf of the OV-1012 Study Investigators (2011) Randomized, phase III study results of clobazam in Lennox-Gastaut Syndrome. Neurology 77: 1473-1481.
14. A receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 26: 229-244.
15. Canadian Clobazam Cooperative Group (1991) Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 32: 407-416.
16. Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, et al. (2009) Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 8: 82-93.
17. Tolbert D, Bekersky I (2013) Pharmacokinetics of N-desmethylclobazam, the Active and Primary Metabolite of Clobazam. 66th Annual Meeting of the American Epilepsy Society. San Diego, California. Epilepsy Currents 13(1 Suppl 1): Abstract #2.226.
18. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, et al. (2004) A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 26: 530-534. (Pubitemid 39463345)
19. Yamamoto Y, Takahashi Y, Imai K, Miyakawa K, Nishimura S, et al. (2013) Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethylclobazam concentrations in patients with epilepsy. Ther Drug Monit 35: 305-312.
20. Klonopin (clonazepam) (2010) [prescribing information]. South San Francisco, CA: Genentech.
21. Ambien (zolpidem) (2013) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC.
22. Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, et al. (2006) TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy) -3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2- and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316: 410-422. (Pubitemid 41832621)
23. A-benzodiazepine receptors produced in transfected cells. Science 245: 1389-1392.
24. 2) via a comprehensive ligand-mapping approach. J Med Chem 43: 71-95.
25. Arendt RM, Greenblatt DJ, Liebisch DC, Luu MD, Paul SM Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. (1987) Psychopharmacology (Berl) 93: 72-76. (Pubitemid 17143729)
26. Haigh JR, Pullar T, Gent JP, Dailley C, Feely M (1987) N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? Br J Clin Pharmacol 23: 213-218. (Pubitemid 17113499)
27. Walzer M, Bekersky I, Blum RA, Tolbert D (2012) Pharmacokinetic Drug Interactions Between Clobazam and Drugs Metabolized by Cytochrome P450 Isoenzymes. Pharmacotherapy 32: 340-353.
28. van der Meyden CH, Bartel PR, Sommers DK, Blom M, Pretorius LC (1989) Effects of clobazam and clonazepam on saccadic eye movements and other parameters of psychomotor performance. Eur J Clin Pharmacol 37: 365-369. (Pubitemid 19276659)
29. Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L (1990) Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol 29: 169-177. (Pubitemid 20131414)
30. Vuilleumier PH, Besson M, Desmeules J, Arendt-Nielsen L, Curatolo M (2013) Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a randomized placebo-controlled study. PLoS One 8(3):e43896. doi: 10.1371/journal.pone.0043896. E-pub 2013 Mar 15.
31. Onfi (clobazam) (2013) [prescribing information]. Deerfield, IL: Lundbeck LLC.
32. Steru L, Chermat R, Millet B, Mico JA, Simon P (1986) Comparative study in mice of ten 1,4-benzodiazepines and of clobazam: anticonvulsant, anxiolytic, sedative, and myorelaxant effects. Epilepsia (Suppl 1): S14-S17. (Pubitemid 16027709)
33. Miura Y, Amano S, Torii R, Ihara N (2002) Clobazam shows a different antiepileptic action profile from clonazepam and zonisamide in Ihara epileptic rats. Epilepsy Res 49: 189-202. (Pubitemid 34655560)